Want to see PETV full AI Analyst Report?
Top Page
PetVivo Holdings
(OTC:PETV)
Select Model
Select Model
Rating:47Neutral
Price Target:
$0.67
▲(4.69% Upside)
Action:Reiterated
Date:08/17/26
The score is held down primarily by weak financial performance—very large losses and heavy cash burn relative to modest revenue—creating meaningful financing risk. Earnings-call progress and strategic initiatives (margin improvement, expense reductions, AI/commercial milestones) provide some offset, but technicals remain weak (below key moving averages) and valuation is constrained by negative earnings and no dividend.
Positive Factors
Revenue growth and high product margins
Revenue growth and a mix shift toward proprietary Spryng support a stronger unit-economics profile. Sustained adoption could lift gross margins and improve operating leverage, although the company must scale sales materially before these benefits can offset its fixed cost base.
Negative Factors
Very small revenue base and persistent losses
The company has not yet demonstrated operating leverage: expenses substantially exceed revenue despite reported growth and improving losses. The small absolute sales base makes profitability highly dependent on rapid commercialization, leaving the business structurally fragile over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue growth and high product margins
Revenue growth and a mix shift toward proprietary Spryng support a stronger unit-economics profile. Sustained adoption could lift gross margins and improve operating leverage, although the company must scale sales materially before these benefits can offset its fixed cost base.
Read all positive factors
PetVivo Holdings (PETV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$24.33M
Dividend YieldN/A
Average Volume (3M)21.60K
Price to Earnings (P/E)―
Beta (1Y)0.08
Revenue Growth-9.54%
EPS Growth18.63%
CountryUS
Employees22
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.31
Shares Outstanding37,950,497
10 Day Avg. Volume14,407
30 Day Avg. Volume21,604
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)9.60
Price to Sales (P/S)18.49
P/FCF Ratio-3.45
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PetVivo Holdings Business Overview & Revenue Model
Company Description
PetVivo Holdings, Inc. operates as a biomedical technology firm, specializing in the invention, commercialization, and licensing of advanced medical devices and biomaterials intended to treat a variety of ailments and diseases affecting animals. I...
How the Company Makes Money
PetVivo makes money primarily by selling its veterinary medical device products, with revenue generated from commercial sales of its osteoarthritis/joint treatment product(s) (including SPRYNG™) into the companion-animal and equine markets. These ...
PetVivo Holdings Earnings Call Summary
Earnings Call Date:Aug 14, 2026
(Q1-2027)
| % Change Since: |
Next Earnings Date:Nov 18, 2026
Earnings Call Sentiment Neutral
The call communicated meaningful commercial, product and technological progress — including double-digit revenue growth, margin improvement, international regulatory recognition, strong AI beta results, and strategic M&A and partnership activity. However, the company remains small in absolute revenue, continues to report operating and net losses, has a tight cash balance ($123k) and depends on pending financing and grants (including a referenced $5M raise to close the PBM acquisition). The positives around product validation, high-margin pipeline opportunities and operational improvements are balanced by liquidity, financing and execution risks.Positive Updates
Revenue Growth
Total revenues increased 13% year-over-year to $338,000 and rose 33% versus the prior quarter, driven by stronger sales of flagship Spryng.
Negative Updates
Weak Absolute Revenue Scale and Ongoing Losses
Despite revenue growth, absolute quarterly revenue remains small at $338,000 and the company reported a net loss of $1.7 million and operating loss of $1.6 million for the quarter.
Read all updates
Q1-2027 Updates
Positive
Negative
Revenue Growth
Total revenues increased 13% year-over-year to $338,000 and rose 33% versus the prior quarter, driven by stronger sales of flagship Spryng.
Read all positive updates
Company Guidance
Management guided continued momentum for fiscal 2027, highlighting Q1 revenue up 13% YoY to $338K (up 33% sequentially) — $276K via distributors and $62K direct — with gross profit $223K (66% margin) and flagship Spryng margin ~90.3%; total operating expenses declined 10% to $1.8M (R&D -31%, G&A -9%, S&M +2%) producing an operating loss of $1.6M and a net loss of $1.7M ($0.05/share), an ~30% improvement from $2.3M ($0.10) a year ago. Cash used in operations fell ~40% to ~$966K (a $668K reduction), ending cash was $123K, and management expects completion of a $1.35M subscription commitment and has discussed a ~$5M capital raise tied to the PBM acquisition (expected to close soon). They forecast higher revenue margins going forward, Health Canada commercialization with Canadian distributors anticipated in 1–2 months, a government grant decision before year‑end, PetVivo.ai commercial launch in the coming months after beta results showing a 50–90% reduction in customer acquisition cost (from $80–$400 to <$43) and 97% diagnostic accuracy, and a new recurring PetVivo.ai revenue stream with projected 80–90% gross margins.PetVivo Holdings Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
41
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.18M | 1.14M | 1.13M | 968.71K | 917.16K | 115.59K |
| Gross Profit | 791.34K | 754.75K | 994.86K | 739.53K | 390.35K | -85.57K |
| EBITDA | -8.27M | -8.86M | -7.69M | -10.49M | -8.62M | -4.99M |
| Net Income | -9.78M | -10.47M | -8.40M | -10.96M | -8.70M | -4.94M |
Balance Sheet | ||||||
| Total Assets | 2.67M | 3.58M | 9.34M | 3.12M | 2.44M | 7.43M |
| Cash, Cash Equivalents and Short-Term Investments | 122.63K | 350.78K | 377.69K | 87.40K | 475.31K | 6.11M |
| Total Debt | 515.11K | 376.16K | 2.90M | 1.37M | 345.33K | 332.85K |
| Total Liabilities | 1.31M | 1.38M | 5.12M | 2.43M | 1.71M | 1.44M |
| Stockholders Equity | 1.36M | 2.20M | 4.22M | 685.95K | 725.02K | 5.99M |
Cash Flow | ||||||
| Free Cash Flow | -5.46M | -6.12M | -5.89M | -7.73M | -7.22M | -4.36M |
| Operating Cash Flow | -5.44M | -6.11M | -5.32M | -7.42M | -6.79M | -4.17M |
| Investing Cash Flow | -8.30K | 11.80K | -563.43K | -309.10K | -423.93K | -183.18K |
| Financing Cash Flow | 2.34M | 6.07M | 6.03M | 7.34M | 1.59M | 10.44M |
PetVivo Holdings Technical Analysis
Negative
0.64
Price Trends
0.73
Negative
0.75
Negative
0.85
Negative
Market Momentum
-0.01
Negative
40.67
Neutral
69.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PETV, the sentiment is Negative. The current price of 0.64 is below the 20-day moving average (MA) of 0.68, below the 50-day MA of 0.73, and below the 200-day MA of 0.85, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 40.67 is Neutral, neither overbought nor oversold. The STOCH value of 69.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PETV.
PetVivo Holdings Risk Analysis
PetVivo Holdings disclosed 35 risk factors in its most recent earnings report. PetVivo Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
PetVivo Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | $1.16B | 17.23 | 28.39% | ― | 3.14% | ― | |
62 Neutral | $282.38M | -78.29 | -2.70% | ― | -2.50% | 93.57% | |
52 Neutral | $617.50M | -14.08 | -11.53% | ― | 14.49% | 6.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $24.33M | -2.17 | -256.06% | ― | -9.54% | 18.63% | |
44 Neutral | $53.87M | -4.67 | -23.45% | ― | -14.27% | -132.84% | |
43 Neutral | $31.43M | -0.91 | 1248.13% | ― | 6.09% | 30.65% |
* Healthcare Sector Average
PETV
PetVivo Holdings
0.64
-0.15
-18.86%
ANIK
Anika Therapeutics
21.10
11.95
130.60%
XTNT
Xtant Medical Holdings
0.38
-0.24
-38.76%
KIDS
OrthoPediatrics
23.65
2.85
13.70%
TELA
TELA Bio
0.70
-1.04
-59.77%
BVS
Bioventus
13.84
6.62
91.69%
PetVivo Holdings Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
PetVivo Ends VetStem License to Refocus on Core Tech
Positive
Jul 29, 2026
On July 24, 2026, PetVivo Holdings Inc. entered into a Termination and Settlement Agreement with VetStem Inc., formally ending their Exclusive License and Supply Agreement covering the PrecisePRP product line and resolving all disputes under that ...
Business Operations and StrategyM&A TransactionsPrivate Placements and Financing
PetVivo to Acquire PiezoBioMembrane, Expanding Biomaterials Platform
Positive
Jun 25, 2026
On June 24, 2026, PetVivo Holdings, Inc., a provider of medical devices and biomedical therapeutics for equines and companion animals, announced an agreement to acquire PiezoBioMembrane, Inc., a developer of advanced functional biomaterials and pi...
Private Placements and Financing
PetVivo Holdings Raises Additional Capital via Private Placement
Positive
Jun 11, 2026
On June 8, 2026, PetVivo Holdings, Inc. received $150,000 in gross proceeds from a partial exercise of an investor purchase option under a March 13, 2026 subscription agreement, bringing total equity raised in this offering to $1,150,000 and total...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.